BRAF抑制剂Braftovi获欧洲药品管理局批准,与EGFR抗体Erbitux联合治疗结直肠癌

2020-06-05 MedSci原创 MedSci原创

Braftovi/Erbitux将总生存期提高了40%,至9.3个月

BRAF抑制剂Braftovi(encorafenib)与EGFR靶向抗体Erbitux(cetuximab)组合,获得欧洲药品监管局的批准用作以前接受过全身性疗法、BRAF阳性结直肠癌患者的二线治疗。

Braftovi于4月在美国获批用于相同适应症。

Braftovi已获批准与MEK抑制剂Mektovi(binimetinib)联合治疗BRAF+黑色素瘤(一种皮肤癌),EvaluatePharma的分析师认为,该药物2024年将占结直肠癌全球预计总销售额12亿美元中的7亿多美元。

临床结果表明,与基于Erbitux和伊立替康的化疗相比,Braftovi/Erbitux将总生存期(OS)提高了40%,中位OS​​分别为5.9个月和9.3个月。

该试验的数据还表明,两种药物联合治疗与包括Mektovi在内的三联疗法一样有效,这意味着可以避免来自MEK抑制剂的额外毒性而不损害患者健康。

大肠癌是第三大最常见的癌症,全球每年约有180万新增患者,其中7-10%患有BRAF突变。

原始出处:

http://www.pmlive.com/pharma_news/pierre_fabres_braftovi_gets_eu_okay_for_braf_colorectal_cancer_1341491

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (14)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1936829, encodeId=adfe1936829ac, content=<a href='/topic/show?id=0c3f1509582' target=_blank style='color:#2F92EE;'>#RAF抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15095, encryptionId=0c3f1509582, topicName=RAF抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca772500164, createdName=ms1490123962508630, createdTime=Mon Jun 15 08:52:13 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785763, encodeId=ba891e85763e0, content=<a href='/topic/show?id=8b40692e75' target=_blank style='color:#2F92EE;'>#Erbitux#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6927, encryptionId=8b40692e75, topicName=Erbitux)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Thu Apr 15 07:52:13 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941521, encodeId=b06a194152132, content=<a href='/topic/show?id=fe6c3661a1' target=_blank style='color:#2F92EE;'>#Braftovi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3661, encryptionId=fe6c3661a1, topicName=Braftovi)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Fri Dec 04 01:52:13 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852394, encodeId=c2b21852394f5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Nov 26 05:52:13 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659422, encodeId=64a1165942219, content=<a href='/topic/show?id=7f998e468c2' target=_blank style='color:#2F92EE;'>#药品管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87468, encryptionId=7f998e468c2, topicName=药品管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 06 18:52:13 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755553, encodeId=21711e55553ad, content=<a href='/topic/show?id=1f8e366977' target=_blank style='color:#2F92EE;'>#BRAF抑制剂Braftovi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3669, encryptionId=1f8e366977, topicName=BRAF抑制剂Braftovi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e37f36960291, createdName=AspirantSuo, createdTime=Mon Nov 16 06:52:13 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313788, encodeId=c26d1313e8807, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339325, encodeId=444313393257b, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355017, encodeId=c9dc135501e9d, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425467, encodeId=93b2142546e19, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63098, encryptionId=b602630980d, topicName=欧洲药品管理局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c44f3972955, createdName=isabellayj, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1936829, encodeId=adfe1936829ac, content=<a href='/topic/show?id=0c3f1509582' target=_blank style='color:#2F92EE;'>#RAF抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15095, encryptionId=0c3f1509582, topicName=RAF抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca772500164, createdName=ms1490123962508630, createdTime=Mon Jun 15 08:52:13 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785763, encodeId=ba891e85763e0, content=<a href='/topic/show?id=8b40692e75' target=_blank style='color:#2F92EE;'>#Erbitux#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6927, encryptionId=8b40692e75, topicName=Erbitux)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Thu Apr 15 07:52:13 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941521, encodeId=b06a194152132, content=<a href='/topic/show?id=fe6c3661a1' target=_blank style='color:#2F92EE;'>#Braftovi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3661, encryptionId=fe6c3661a1, topicName=Braftovi)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Fri Dec 04 01:52:13 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852394, encodeId=c2b21852394f5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Nov 26 05:52:13 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659422, encodeId=64a1165942219, content=<a href='/topic/show?id=7f998e468c2' target=_blank style='color:#2F92EE;'>#药品管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87468, encryptionId=7f998e468c2, topicName=药品管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 06 18:52:13 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755553, encodeId=21711e55553ad, content=<a href='/topic/show?id=1f8e366977' target=_blank style='color:#2F92EE;'>#BRAF抑制剂Braftovi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3669, encryptionId=1f8e366977, topicName=BRAF抑制剂Braftovi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e37f36960291, createdName=AspirantSuo, createdTime=Mon Nov 16 06:52:13 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313788, encodeId=c26d1313e8807, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339325, encodeId=444313393257b, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355017, encodeId=c9dc135501e9d, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425467, encodeId=93b2142546e19, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63098, encryptionId=b602630980d, topicName=欧洲药品管理局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c44f3972955, createdName=isabellayj, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1936829, encodeId=adfe1936829ac, content=<a href='/topic/show?id=0c3f1509582' target=_blank style='color:#2F92EE;'>#RAF抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15095, encryptionId=0c3f1509582, topicName=RAF抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca772500164, createdName=ms1490123962508630, createdTime=Mon Jun 15 08:52:13 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785763, encodeId=ba891e85763e0, content=<a href='/topic/show?id=8b40692e75' target=_blank style='color:#2F92EE;'>#Erbitux#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6927, encryptionId=8b40692e75, topicName=Erbitux)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Thu Apr 15 07:52:13 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941521, encodeId=b06a194152132, content=<a href='/topic/show?id=fe6c3661a1' target=_blank style='color:#2F92EE;'>#Braftovi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3661, encryptionId=fe6c3661a1, topicName=Braftovi)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Fri Dec 04 01:52:13 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852394, encodeId=c2b21852394f5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Nov 26 05:52:13 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659422, encodeId=64a1165942219, content=<a href='/topic/show?id=7f998e468c2' target=_blank style='color:#2F92EE;'>#药品管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87468, encryptionId=7f998e468c2, topicName=药品管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 06 18:52:13 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755553, encodeId=21711e55553ad, content=<a href='/topic/show?id=1f8e366977' target=_blank style='color:#2F92EE;'>#BRAF抑制剂Braftovi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3669, encryptionId=1f8e366977, topicName=BRAF抑制剂Braftovi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e37f36960291, createdName=AspirantSuo, createdTime=Mon Nov 16 06:52:13 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313788, encodeId=c26d1313e8807, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339325, encodeId=444313393257b, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355017, encodeId=c9dc135501e9d, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425467, encodeId=93b2142546e19, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63098, encryptionId=b602630980d, topicName=欧洲药品管理局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c44f3972955, createdName=isabellayj, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=)]
    2020-12-04 3631173
  4. [GetPortalCommentsPageByObjectIdResponse(id=1936829, encodeId=adfe1936829ac, content=<a href='/topic/show?id=0c3f1509582' target=_blank style='color:#2F92EE;'>#RAF抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15095, encryptionId=0c3f1509582, topicName=RAF抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca772500164, createdName=ms1490123962508630, createdTime=Mon Jun 15 08:52:13 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785763, encodeId=ba891e85763e0, content=<a href='/topic/show?id=8b40692e75' target=_blank style='color:#2F92EE;'>#Erbitux#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6927, encryptionId=8b40692e75, topicName=Erbitux)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Thu Apr 15 07:52:13 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941521, encodeId=b06a194152132, content=<a href='/topic/show?id=fe6c3661a1' target=_blank style='color:#2F92EE;'>#Braftovi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3661, encryptionId=fe6c3661a1, topicName=Braftovi)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Fri Dec 04 01:52:13 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852394, encodeId=c2b21852394f5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Nov 26 05:52:13 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659422, encodeId=64a1165942219, content=<a href='/topic/show?id=7f998e468c2' target=_blank style='color:#2F92EE;'>#药品管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87468, encryptionId=7f998e468c2, topicName=药品管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 06 18:52:13 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755553, encodeId=21711e55553ad, content=<a href='/topic/show?id=1f8e366977' target=_blank style='color:#2F92EE;'>#BRAF抑制剂Braftovi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3669, encryptionId=1f8e366977, topicName=BRAF抑制剂Braftovi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e37f36960291, createdName=AspirantSuo, createdTime=Mon Nov 16 06:52:13 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313788, encodeId=c26d1313e8807, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339325, encodeId=444313393257b, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355017, encodeId=c9dc135501e9d, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425467, encodeId=93b2142546e19, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63098, encryptionId=b602630980d, topicName=欧洲药品管理局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c44f3972955, createdName=isabellayj, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=)]
    2020-11-26 jklm09
  5. [GetPortalCommentsPageByObjectIdResponse(id=1936829, encodeId=adfe1936829ac, content=<a href='/topic/show?id=0c3f1509582' target=_blank style='color:#2F92EE;'>#RAF抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15095, encryptionId=0c3f1509582, topicName=RAF抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca772500164, createdName=ms1490123962508630, createdTime=Mon Jun 15 08:52:13 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785763, encodeId=ba891e85763e0, content=<a href='/topic/show?id=8b40692e75' target=_blank style='color:#2F92EE;'>#Erbitux#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6927, encryptionId=8b40692e75, topicName=Erbitux)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Thu Apr 15 07:52:13 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941521, encodeId=b06a194152132, content=<a href='/topic/show?id=fe6c3661a1' target=_blank style='color:#2F92EE;'>#Braftovi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3661, encryptionId=fe6c3661a1, topicName=Braftovi)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Fri Dec 04 01:52:13 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852394, encodeId=c2b21852394f5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Nov 26 05:52:13 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659422, encodeId=64a1165942219, content=<a href='/topic/show?id=7f998e468c2' target=_blank style='color:#2F92EE;'>#药品管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87468, encryptionId=7f998e468c2, topicName=药品管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 06 18:52:13 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755553, encodeId=21711e55553ad, content=<a href='/topic/show?id=1f8e366977' target=_blank style='color:#2F92EE;'>#BRAF抑制剂Braftovi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3669, encryptionId=1f8e366977, topicName=BRAF抑制剂Braftovi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e37f36960291, createdName=AspirantSuo, createdTime=Mon Nov 16 06:52:13 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313788, encodeId=c26d1313e8807, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339325, encodeId=444313393257b, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355017, encodeId=c9dc135501e9d, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425467, encodeId=93b2142546e19, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63098, encryptionId=b602630980d, topicName=欧洲药品管理局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c44f3972955, createdName=isabellayj, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1936829, encodeId=adfe1936829ac, content=<a href='/topic/show?id=0c3f1509582' target=_blank style='color:#2F92EE;'>#RAF抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15095, encryptionId=0c3f1509582, topicName=RAF抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca772500164, createdName=ms1490123962508630, createdTime=Mon Jun 15 08:52:13 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785763, encodeId=ba891e85763e0, content=<a href='/topic/show?id=8b40692e75' target=_blank style='color:#2F92EE;'>#Erbitux#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6927, encryptionId=8b40692e75, topicName=Erbitux)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Thu Apr 15 07:52:13 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941521, encodeId=b06a194152132, content=<a href='/topic/show?id=fe6c3661a1' target=_blank style='color:#2F92EE;'>#Braftovi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3661, encryptionId=fe6c3661a1, topicName=Braftovi)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Fri Dec 04 01:52:13 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852394, encodeId=c2b21852394f5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Nov 26 05:52:13 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659422, encodeId=64a1165942219, content=<a href='/topic/show?id=7f998e468c2' target=_blank style='color:#2F92EE;'>#药品管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87468, encryptionId=7f998e468c2, topicName=药品管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 06 18:52:13 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755553, encodeId=21711e55553ad, content=<a href='/topic/show?id=1f8e366977' target=_blank style='color:#2F92EE;'>#BRAF抑制剂Braftovi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3669, encryptionId=1f8e366977, topicName=BRAF抑制剂Braftovi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e37f36960291, createdName=AspirantSuo, createdTime=Mon Nov 16 06:52:13 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313788, encodeId=c26d1313e8807, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339325, encodeId=444313393257b, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355017, encodeId=c9dc135501e9d, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425467, encodeId=93b2142546e19, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63098, encryptionId=b602630980d, topicName=欧洲药品管理局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c44f3972955, createdName=isabellayj, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1936829, encodeId=adfe1936829ac, content=<a href='/topic/show?id=0c3f1509582' target=_blank style='color:#2F92EE;'>#RAF抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15095, encryptionId=0c3f1509582, topicName=RAF抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca772500164, createdName=ms1490123962508630, createdTime=Mon Jun 15 08:52:13 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785763, encodeId=ba891e85763e0, content=<a href='/topic/show?id=8b40692e75' target=_blank style='color:#2F92EE;'>#Erbitux#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6927, encryptionId=8b40692e75, topicName=Erbitux)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Thu Apr 15 07:52:13 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941521, encodeId=b06a194152132, content=<a href='/topic/show?id=fe6c3661a1' target=_blank style='color:#2F92EE;'>#Braftovi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3661, encryptionId=fe6c3661a1, topicName=Braftovi)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Fri Dec 04 01:52:13 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852394, encodeId=c2b21852394f5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Nov 26 05:52:13 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659422, encodeId=64a1165942219, content=<a href='/topic/show?id=7f998e468c2' target=_blank style='color:#2F92EE;'>#药品管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87468, encryptionId=7f998e468c2, topicName=药品管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 06 18:52:13 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755553, encodeId=21711e55553ad, content=<a href='/topic/show?id=1f8e366977' target=_blank style='color:#2F92EE;'>#BRAF抑制剂Braftovi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3669, encryptionId=1f8e366977, topicName=BRAF抑制剂Braftovi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e37f36960291, createdName=AspirantSuo, createdTime=Mon Nov 16 06:52:13 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313788, encodeId=c26d1313e8807, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339325, encodeId=444313393257b, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355017, encodeId=c9dc135501e9d, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425467, encodeId=93b2142546e19, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63098, encryptionId=b602630980d, topicName=欧洲药品管理局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c44f3972955, createdName=isabellayj, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1936829, encodeId=adfe1936829ac, content=<a href='/topic/show?id=0c3f1509582' target=_blank style='color:#2F92EE;'>#RAF抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15095, encryptionId=0c3f1509582, topicName=RAF抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca772500164, createdName=ms1490123962508630, createdTime=Mon Jun 15 08:52:13 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785763, encodeId=ba891e85763e0, content=<a href='/topic/show?id=8b40692e75' target=_blank style='color:#2F92EE;'>#Erbitux#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6927, encryptionId=8b40692e75, topicName=Erbitux)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Thu Apr 15 07:52:13 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941521, encodeId=b06a194152132, content=<a href='/topic/show?id=fe6c3661a1' target=_blank style='color:#2F92EE;'>#Braftovi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3661, encryptionId=fe6c3661a1, topicName=Braftovi)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Fri Dec 04 01:52:13 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852394, encodeId=c2b21852394f5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Nov 26 05:52:13 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659422, encodeId=64a1165942219, content=<a href='/topic/show?id=7f998e468c2' target=_blank style='color:#2F92EE;'>#药品管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87468, encryptionId=7f998e468c2, topicName=药品管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 06 18:52:13 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755553, encodeId=21711e55553ad, content=<a href='/topic/show?id=1f8e366977' target=_blank style='color:#2F92EE;'>#BRAF抑制剂Braftovi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3669, encryptionId=1f8e366977, topicName=BRAF抑制剂Braftovi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e37f36960291, createdName=AspirantSuo, createdTime=Mon Nov 16 06:52:13 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313788, encodeId=c26d1313e8807, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339325, encodeId=444313393257b, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355017, encodeId=c9dc135501e9d, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425467, encodeId=93b2142546e19, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63098, encryptionId=b602630980d, topicName=欧洲药品管理局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c44f3972955, createdName=isabellayj, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1936829, encodeId=adfe1936829ac, content=<a href='/topic/show?id=0c3f1509582' target=_blank style='color:#2F92EE;'>#RAF抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15095, encryptionId=0c3f1509582, topicName=RAF抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca772500164, createdName=ms1490123962508630, createdTime=Mon Jun 15 08:52:13 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785763, encodeId=ba891e85763e0, content=<a href='/topic/show?id=8b40692e75' target=_blank style='color:#2F92EE;'>#Erbitux#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6927, encryptionId=8b40692e75, topicName=Erbitux)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Thu Apr 15 07:52:13 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941521, encodeId=b06a194152132, content=<a href='/topic/show?id=fe6c3661a1' target=_blank style='color:#2F92EE;'>#Braftovi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3661, encryptionId=fe6c3661a1, topicName=Braftovi)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Fri Dec 04 01:52:13 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852394, encodeId=c2b21852394f5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Nov 26 05:52:13 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659422, encodeId=64a1165942219, content=<a href='/topic/show?id=7f998e468c2' target=_blank style='color:#2F92EE;'>#药品管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87468, encryptionId=7f998e468c2, topicName=药品管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 06 18:52:13 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755553, encodeId=21711e55553ad, content=<a href='/topic/show?id=1f8e366977' target=_blank style='color:#2F92EE;'>#BRAF抑制剂Braftovi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3669, encryptionId=1f8e366977, topicName=BRAF抑制剂Braftovi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e37f36960291, createdName=AspirantSuo, createdTime=Mon Nov 16 06:52:13 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313788, encodeId=c26d1313e8807, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339325, encodeId=444313393257b, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355017, encodeId=c9dc135501e9d, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425467, encodeId=93b2142546e19, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63098, encryptionId=b602630980d, topicName=欧洲药品管理局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c44f3972955, createdName=isabellayj, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=)]
    2020-06-07 zhaojie88
  10. [GetPortalCommentsPageByObjectIdResponse(id=1936829, encodeId=adfe1936829ac, content=<a href='/topic/show?id=0c3f1509582' target=_blank style='color:#2F92EE;'>#RAF抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15095, encryptionId=0c3f1509582, topicName=RAF抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca772500164, createdName=ms1490123962508630, createdTime=Mon Jun 15 08:52:13 CST 2020, time=2020-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785763, encodeId=ba891e85763e0, content=<a href='/topic/show?id=8b40692e75' target=_blank style='color:#2F92EE;'>#Erbitux#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6927, encryptionId=8b40692e75, topicName=Erbitux)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Thu Apr 15 07:52:13 CST 2021, time=2021-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941521, encodeId=b06a194152132, content=<a href='/topic/show?id=fe6c3661a1' target=_blank style='color:#2F92EE;'>#Braftovi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3661, encryptionId=fe6c3661a1, topicName=Braftovi)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Fri Dec 04 01:52:13 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1852394, encodeId=c2b21852394f5, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Nov 26 05:52:13 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1659422, encodeId=64a1165942219, content=<a href='/topic/show?id=7f998e468c2' target=_blank style='color:#2F92EE;'>#药品管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87468, encryptionId=7f998e468c2, topicName=药品管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Feb 06 18:52:13 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755553, encodeId=21711e55553ad, content=<a href='/topic/show?id=1f8e366977' target=_blank style='color:#2F92EE;'>#BRAF抑制剂Braftovi#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3669, encryptionId=1f8e366977, topicName=BRAF抑制剂Braftovi)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e37f36960291, createdName=AspirantSuo, createdTime=Mon Nov 16 06:52:13 CST 2020, time=2020-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313788, encodeId=c26d1313e8807, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339325, encodeId=444313393257b, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355017, encodeId=c9dc135501e9d, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3659, encryptionId=6de63659ed, topicName=BRAF)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1425467, encodeId=93b2142546e19, content=<a href='/topic/show?id=b602630980d' target=_blank style='color:#2F92EE;'>#欧洲药品管理局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63098, encryptionId=b602630980d, topicName=欧洲药品管理局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c44f3972955, createdName=isabellayj, createdTime=Sun Jun 07 09:52:13 CST 2020, time=2020-06-07, status=1, ipAttribution=)]

相关资讯

NAT COMMUN:禁食加Vc,抗癌得力组合

饥饿模拟饮食可延缓肿瘤的进展,并使多种肿瘤对化疗产生敏感性,但至今为止,我们对其与非细胞毒性化合物联合使用的治疗潜力尚不甚了解。

Cell Death Dis:肿瘤相关成纤维细胞可影响结肠癌细胞的生理节律

生物钟可以调节蛋白质的表达水平及其功能特性,如细胞生长相关的节律,而这些作用能够调节细胞稳态和组织的整体活性。

CTM:用列线图预测结直肠癌患者特定位点远处转移和总体生存大规模人群研究

在美国仅2019年就有148000名新结直肠癌(CRC)患者,其中每天有146名患者死亡,占所有恶性肿瘤死亡率的第三位。在过去的30年间,CRC在全世界范围内的发病率和总体生存率(OS)一直在升高。5

NAT COMMUN:TGF-β信号促进IL-22的产生,从而促进结肠癌的产生

IL-22在肿瘤发生过程中具有双重功能。短期内IL-22的产生可保护细胞免受基因毒性应激,而不受控制的IL-22作用则促进肿瘤生长;因此,对IL-22的严密调控至关重要。

PNAS:中山大学高国全团队发现,二甲双胍对KRAS突变型结直肠癌有效

我国研究人员发现,与其他降糖药联合标准系统治疗的糖尿病KRAS突变-mCRC患者相比,使用二甲双胍的患者中位生存时间延长了37.8个月。

Cell Death Dis:BECN1在结直肠癌转移中的作用及潜在机制

细胞自噬是一种涉及捕获、降解和回收溶酶体中的细胞内蛋白和细胞器的促生存反应。癌症中细胞自噬作用的增强能够促进肿瘤微环境中癌细胞的存活率,促进癌细胞的生长和侵袭能力。